Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
4.99M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
69.8M
-
Shares change
-
-332K
-
Total reported value, excl. options
-
$947M
-
Value change
-
-$9.19M
-
Number of buys
-
66
-
Number of sells
-
-58
-
Price
-
$13.58
Significant Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) as of Q2 2021
159 filings reported holding MRSN - Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2021.
Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 69.8M shares
.
Largest 10 shareholders include BlackRock Inc. (8.82M shares), WELLINGTON MANAGEMENT GROUP LLP (6.88M shares), Avoro Capital Advisors LLC (6.8M shares), Sarissa Capital Management LP (4.01M shares), Bain Capital Life Sciences Investors, LLC (3.7M shares), STATE STREET CORP (3.25M shares), VANGUARD GROUP INC (3.18M shares), Bellevue Group AG (2.94M shares), Rock Springs Capital Management LP (2.85M shares), and ORBIMED ADVISORS LLC (2.8M shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.